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138 The Journal of Thoracic and CardioBackground: Arteriogenesis has been implicated as an important biologic response to
acute vascular occlusion. The early growth response 1 (Egr-1) gene encodes an imme-
diate-early response transcription factor that is upregulated by changes in vascular strain
and that in turn upregulates a number of putative angiogenic and arteriogenic growth
factors. We therefore hypothesized that early growth response 1 might be a critical
arteriogenic messenger that induces revascularization in the setting of acute vascular
occlusions.
Methods: Wild-type or Egr-1/ (null) C57 BL mice, or Sprague-Dawley rats, under-
went unilateral iliofemoral artery excision and subsequent analyses for angiogenesis and
arteriogenesis through cell-specific immunohistochemistry. Rats were also administered
an adenoviral vector encoding for Egr-1 (AdEgr group), noncoding vectors (AdNull
group), or saline, after which these animals were assessed by means of serial laser
Doppler perfusion imaging and morphologic examination of rat foot-pad ischemic
lesions.
Results: Egr-1 wild-type mice demonstrated an equivalent number of capillaries but a
greater number of arterioles following excision versus Egr-1 null mice. AdEgr group
rats demonstrated greater distal perfusion from 7 to 21 days after excision compared
with control animals (P  .02), which approximated normal perfusion at 21 days after
excision. AdEgr group rats also demonstrated greater arteriolar density and less severe
ischemic foot-pad lesions than control animals.
Conclusion: These data suggest the importance of Egr-1 as a critical and potentially
therapeutic mediator of revascularization after vascular occlusion and implicate arterio-
genesis (collateral vessel formation) as a critical component of this process.
Recognition of the central role played by angiogenic growth factors in theendogenous processes of tissue vascularization has led to the development of astrategy of therapeutic angiogenesis, wherein exogenous growth factors are
administered to ischemic tissues to enhance the reperfusion of these tissues.1-7 Recent
evidence suggests, however, that the administration of angiogenic mediators, such as
vascular endothelial growth factor (VEGF), that might primarily induce capillary
formation might also not be sufficient to induce stable neovascularization or to induce
collateral vessel formation or arteriogenesis.8-13 Moreover, because the development of
a mature and robust vascular network would seem to optimally require a precise spatial
and temporal regulation of a large number of angiogenic stimulators, arteriogenic
stimulators, or both and cofactors, it might be preferable, as opposed to the prevalent
current practice of administering isolated growth factors, to deliver a transcription factor
that upregulates the downstream expression of the various growth factors as would
occur under endogenous regulatory mechanisms.
The early growth response (Egr) 1 transcription factor (also known as zif 268, TIS
8, nerve growth factor induced A, and Krox 24) is an 80- to 82-kd, 533-amino-acid
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ETresidue protein that is the prototypical member of the imme-
diate-early gene family of zinc-finger transcription factors that
includes Egr-2, Egr-3, and Egr-4.14,15 Expression of this plu-
ripotent transcription factor is modulated by changes in vas-
cular wall shear stress that would occur in the setting of an
acute vascular occlusion and directly or indirectly results in the
upregulated expression of numerous growth factors implicated
in both angiogenesis and arteriogenesis.16-19 Egr-1 is thus an
intriguing potential mediator of revascularization responses to
acute vascular occlusions. In this regard we recently demon-
strated that Egr-1 null (knockout) mice subjected to femoral
artery excision demonstrate a nearly complete absence of re-
vascularization competency.20 We therefore hypothesized and
now report data demonstrating a deficiency in arteriogenesis in
Egr-1 null animals and that the therapeutic administration of
Egr-1 in wild-type animals is capable of inducing a robust
revascularization in the setting of acute vascular occlusion.
Materials and Methods
Egr-1 Knockout Animals
A colony of Egr-1/ (null) C57 BL/6 mice (gift of Dr Jeffrey
Milbrandt, Washington University, St Louis, Mo.)21,22 was estab-
lished at the Coon Research Center at Evanston Northwestern Health-
care by using standard breeding procedures. Animal handling at all
times was in accordance with institutional animal care and use com-
mittee guidelines. Animals selected from this colony underwent geno-
typing at 25 days after birth, as previously described, 20 after which
Egr-1 null or wild-type animals underwent experimental studies at
approximately 2 to 4 months of age.
Gene Transfer Vectors
The Egr-1 transfer vector (adenoviral vector encoding for Egr-1
[AdEgr]) used in these studies was an E1a, partial E1b, partial E3
adenovirus vector based on human adenovirus serotype 5 containing
the cytomegalovirus early promoter–enhancer driving the comple-
mentary DNA for Egr-1, which was prepared as previously described
(gift of J. Milbrandt).23,24 As a negative control, a similar adenovirus
containing no gene in the expression cassette (AdNull) was used.
Vector competency was assessed on HT1080 cells (American Type
Culture Collection no. CCl-121), which were treated with 50 vector
pu/cell. Cells were harvested into Trizol Reagent (Invitrogen, Carls-
bad, Calif), and RNA was purified, reverse transcribed, and subjected
to semiquantitative polymerase chain reaction by using rat Egr-1
Abbreviations and Acronyms
AdEgr-1 adenoviral vector encoding for Egr-1
AdNull  noncoding vector
Egr-1  early growth response transcription factor 1
LDPI  laser Doppler perfusion imaging
PBS  phosphate-buffered saline
ROI  region of interest
SMA  smooth muscle actin
VEGF  vascular endothelial growth factorprimers (GenBank accession no. NM_012551).20
The Journal of ThoraciVascular Excision in Mice
Wild-type or homozygous Egr-1–deleted (null) mice (25 g) selected
from the C57 BL/6 mouse colony were anesthetized with pentobar-
bital (60 mg/kg administered intraperitoneally) after induction with a
mixture of isoflurane (3.5 L/min) and 100% oxygen (3 L/min). A
midline abdominal incision was then made, and the proximal end of
the femoral artery at the inguinal ligament and the distal portion of the
saphenous artery were ligated with 4-0 silk sutures. The artery and all
side branches were then dissected free, and this entire vascular seg-
ment was removed (type I preparation).25 The incision was then
closed, and the animals were recovered as per standard protocols.
Adenoviral Vector Injection in Rats
For therapeutic studies, male Sprague-Dawley rats (250-320 g; Harlan
Sprague Dawley, Inc, Indianapolis, Ind) treated in accordance with
institutional care and use committee guidelines underwent anesthetic
induction with a mixture of ketamine (80 mg/kg administered intra-
peritoneally) and xylazine (12 mg/kg administered intraperitoneally).
The rats were placed in the dorsal decubitus position, and the abdo-
men and both inferior limbs were shaved and cleaned with povidone-
iodine solution. As opposed to the type I femoral excision preparation
used in mice to minimize necrosis in the interest of histologic studies,
a more extensive (type II) iliofemoral excision model was created in
rats to create a maximal degree of ischemia to conduct physiologic
and morphologic studies of the effects of AdEgr administration on
distal perfusion and revascularization. The retroperitoneal space on
the left side was entered through a midline abdominal incision, and
the common iliac artery was dissected free and ligated. The abdomen
was closed in anatomic layers. Immediately thereafter, a left groin
incision was performed, and the common, superficial, and deep fem-
oral arteries and veins were dissected free. The common proximal,
superficial, and deep femoral arteries and veins were ligated and
excised, whereas the most proximal perforant branch of the common
femoral artery was carefully preserved.
Six separate 20-L injections of 2  109 pu (total dose: 1.2 
1010 pu diluted in 120 L of phosphate-buffered saline [PBS]) of
AdEgr (n  8) or AdNull (n  7) or 120 L of PBS (n  7) were
then delivered into the adductor muscles by using the muscular branch
of the common femoral artery as a landmark. The groin incision was
then closed with a running suture, and the animals were allowed to
recover according to standard protocols. All the procedures were
performed by the same operator, and the identity of the animals was
revealed only at the end of the study (postoperative day 21).
Laser Doppler Perfusion
Laser Doppler perfusion imaging (LDPI) was used to measure distal
hind-limb perfusion preoperatively and at serial time points after
vascular excision (immediately after surgical intervention and at post-
operative days 1, 3, 7, 14, and 21). Duplicate laser Doppler perfusion
images were obtained in a blinded manner by using an LDPI system
(Perimed, Jarfalla, Sweden) through clipped and depilated hind-limb
skin surfaces after placing the rats on a 37°C heating pad for 10
minutes. Regions of interest (ROIs) encompassing either the entire
ligated or the contralateral nonligated hind limb were analyzed with
accessory software (Patch Test) provided by the manufacturer, as
previously described.25 More specifically, the ROIs were determined
by using color images of the ventral surface of the hind limbs by
placing a standard, computer-generated rectangle over the most distal
c and Cardiovascular Surgery ● Volume 131, Number 1 139
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calculate a mean intensity of Doppler signal within the ROI. A
perfusion index for each animal was expressed as the average of the
ratios of the ROIs for the ligated versus the contralateral, nonligated
limb to minimize data variables caused by ambient light and
temperature.
Clinical Ischemia Score
Rats were observed for evidence of ischemic hind-limb lesions after
anesthetic induction and LDPI scanning at days 7, 14, and 21 post-
excision. A severity scale was established from prior standards 26 on
the basis of the characteristics of the lesions on the hind limbs and
paws, as follows: 1, normal; 2, healed pressure sores (trace soft
tissue loss without scab); 3, nonhealed pressure sores (partial thick-
ness-skin loss covered with scab); 4, gangrene of the tips of the toes;
and 5, gangrene with amputation of phalanges-toes. Photographs
(Sony Cybershot DSC P72 Camera) were taken for each animal at the
intervals described, stored, and analyzed in a blinded fashion.
Histology
Animals were killed at either day 7 or day 21 after excision by
means of pentobarbital overdose. The adductor musculature
was excised and fixed with zinc-formalin before paraffin em-
bedding. Sections taken at 100-m intervals with a 5-m
thickness were prepared for immunohistochemical staining with
avidin/horseradish peroxidase with chromogenic developing re-
agents and were hematoxylin and eosin counterstained. Sections
were labeled with biotinylated smooth muscle actin (SMA)
monoclonal antibody (Dako, Carpinteria, Calif) or biotinylated
Galanthus nivalis lectin specific to rodent endothelial cells
(Vector Laboratories, Burlington, Calif). SMA-positive vessels
and lectin-positive vessels were counted from 6 randomly se-
lected (200) fields in a blinded manner assisted by Metamorph
Figure 1. Quantitative analysis of perfusion index, calculated as
described in the Methods section. Note near normalization (index
approximately 1) of perfusion in AdEgr-treated animals at day 21.
AdEgr-1, Adenoviral vector encoding for Egr-1; PBS, phosphate-
buffered saline; AdNull, noncoding vector.Software (Universal Imaging, Downingtown, Pa). Specific
140 The Journal of Thoracic and Cardiovascular Surgery ● Januquantification was also made of the number of vessels per field
measuring 50  m or larger (arterioles).10
Statistical Analysis
Data are expressed as means and standard deviations. One-way anal-
ysis of variance or 2 analysis, followed by the post hoc Bonferonni
correction, was used to compare results between groups, as
appropriate.
Results
Arteriogenesis Deficit in Egr-1 Null Animals
Specimens from the ischemic limbs of Egr-1 null and
wild-type mice obtained 21 days after femoral artery
excision (type I preparation) were assessed for evidence
of arteriogenesis and angiogenesis. Egr-1 null mice dem-
onstrated fewer arterioles per microscopic field compared
with wild-type mice (14  5 for Egr-1 null mice vs 22 
2 for wild-type mice, P  .06), but an equivalent number
of capillaries (115  24 for Egr-1 null mice vs 104  41
for wild-type mice). The morphology of both large and
small vessels was similar in null compared with wild-
Figure 2. Laser Doppler perfusion imaging at days 7 and 21 after
excision. Low or no blood perfusion is displayed as dark blue,
and the highest perfusion level is displayed as red. Note early
reconstitution of flow in AdEgr-1–treated animals and near equal-
ization at day 21. PBS, Phosphate-buffered saline; AdNull, non-
coding vector; AdEgr-1, adenoviral vector encoding for Egr-1.type animals (data not shown).
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Laser Doppler Perfusion Analysis
Laser Doppler perfusion analysis was performed on rats having
undergone iliofemoral artery excision (type II preparation) and
administration of AdEgr, AdNull, or PBS. The ligated/nonligated
hind-limb perfusion index was equivalent (approximately 1) at
baseline in all groups (Figure 1). Immediately after vascular ex-
cision, the ratio of ligated/nonligated hind-limb perfusion de-
creased to a similar extent in all groups (range, 0.34-0.38). The
recovery of limb perfusion accelerated in a first phase between
days 3 and 7 after excision, with the steepest slope demonstrated
by the AdEgr-1–treated group when compared with the PBS- and
AdNull-treated groups (day 7 perfusion index: 0.76  0.08 for
Figure 3. Top, Representative lesions as seen 21 days a
without scab (2); b, nonhealed pressure sores, partial th
the tips of the toes (4); and d, gangrene with amputatio
details. Bottom, Distribution of lesions between groups.AdEgr vs 0.68 0.13 for PBS and 0.58 0.07 for AdNull, P
The Journal of Thoraci.01). Although the rate of improvement in perfusion slowed there-
after, AdEgr-1–treated animals demonstrated comparatively
greater distal perfusion of the ligated versus the nonligated hind
limb than did control animals at day 21 after excision (Figure 2).
Distal perfusion in AdEgr-treated animals reapproximated base-
line values, which was significantly greater than that seen in
control animals (day 21 perfusion index: 0.97  0.1 for AdEgr-
1–treated animals vs 0.73  0.11 for PBS-treated animals and
0.75  0.12 for AdNull-treated animals, P  .006).
Clinical Ischemia Score
Footpads of the ischemic rat hind limbs demonstrated isch-
xcision: a, healed pressure sores, soft tissue loss trace
ess and skin loss covered with scab (3); c, necrosis of
halanges-toes (5). Please see the Methods section for
r, adenoviral vector encoding for Egr.fter e
ickn
n of p
AdEgemic lesions ranging from pressure sores to gangrene by 14
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AdEgr-1–treated group demonstrated the least number of
lesions in the most severe lesion classes (Figure 3) and less
severe lesions overall compared with PBS- and AdNull-in-
jected animals (mean ischemic score: 2.7  0.5 vs 3.2  1.0
and 4.1  0.9, respectively; P  .17). Of note, gangrenous
lesions (lesion score 4 or 5) were noted in none of the
AdEgr-1–treated group compared with 7 (50%) of the AdNull-
treated animals or PBS-treated control animals, respectively
(P  .05).
Histology
AdEgr-treated rats demonstrated nearly twice as many
SMA-positive vessels (arterioles) at day 7 after excision
Figure 4. Density of arterioles and capillaries in lig
identified with smooth muscle cell actin (A) and le
Egr, early growth response gene (Ad transfer).as did AdNull- or PBS-treated control animals (130  11
142 The Journal of Thoracic and Cardiovascular Surgery ● Januvs 70  6 and 80  19, respectively; P  .001). AdEgr-
treated animals still demonstrated approximately 20%
more SMA-positive vessels per microscopic field than
did control animals by day 21 after excision, although the
total number of such vessels had decreased in each group
(Figure 4). The number of SMA-positive vessels measur-
ing at least 50 m in diameter (arterioles) demonstrated
a similar trend (day 7: 14  3 for AdEgr-treated animals
and 5  4 for AdNull-treated animals, P  .013; day 21:
4  1 for AdEgr-treated animals and 3  0 for AdNull-
treated animals, P  .18). In contrast, the total number of
capillaries, as detected by means of lectin staining, was
equivalent between groups at both the 7- and 21-day time
points. The morphology of both large and small vessels was
rat hind limb 21 days after specified treatments, as
stains (B), respectively. SMA, Smooth muscle actin;ated
ctinsimilar in AdEgr-treated and untreated animals (Figure 5).
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A growing body of data suggest that Egr-1 plays an important
role in a number of vascular homeostatic mechanisms, includ-
ing those that might translate physiologic factors, such as shear
stress and hypoxia, into modulation of gene expression and
biologic responses, potentially including neovascularization
Figure 5. Photomicrographs of arterioles and capillaries i
by smooth muscle cell actin (A) and lectin stains (L), re
(AdEgr); middle panels, phosphate-buffered saline (PBS);after vascular occlusion.14-20,27-29 The apparent importance of
The Journal of ThoraciEgr-1 in a pneumonectomy-contralateral lung growth model
that we have previously reported30 and the known biologic
properties of Egr-1 that would be relevant to the hemodynamic
changes expected with naturally occurring atherosclerotic vas-
cular occlusions led us to suspect that Egr-1 might represent
the previously missing signaling factor capable of translating
ted rat hind limbs after specified treatments, as identified
tively. Top panels, adenoviral vector encoding for Egr-1
m panels, noncoding vectors (AdNull).n liga
spec
bottothe physiologic sequelae of vascular occlusion into the homeo-
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biologic perturbation.
Our prior findings of essentially absent revascularization
after vascular excision in an Egr-1 knockout mouse model
supported our premise of the criticality of Egr-1 in postocclu-
sive neovascularization processes.20 Consistent with these pre-
vious results, we now demonstrate a relative deficiency spe-
cifically in arteriogenesis in Egr-1 null versus wild-type mice
and near-normalization of distal perfusion after AdEgr admin-
istration to ligated rats, apparently through a primarily arterio-
genic process. These findings provide evidence that arteriogen-
esis is a critical mechanism underlying endogenous
neovascularization processes and suggest a new means of
providing for robust reperfusion in the treatment of atheroscle-
rosis and vascular occlusive disease.
The present findings that Egr-1 deletion or administration
appears primarily to affect the development of arterioles, rather
than capillaries, are intriguing given the known molecular
pathways governed by the Egr-1 transcription factor. More
specifically, Egr-1 is known to upregulate the expression of
genes, such as platelet-derived growth factor A and B and
transforming growth factor , implicated in smooth muscle
cell recruitment and arteriogenesis and, indirectly through
transforming growth factor , upregulate a number of growth
factors, including VEGF, and metalloproteinases that are re-
sponsible for angiogenesis and vascular formation.14-19 By
using smooth muscle cell actin staining as a marker of vascular
smooth muscle recruitment and arteriolar development,31 the
current findings suggest that although arteriogenesis might be
closely linked to Egr-1 expression, angiogenesis might be
mediated by pathways independent of Egr-1.
Much uncertainty surrounds the postnatal roles and
relative physiologic importance of angiogenesis, the
sprouting, bridging, and intussusceptive growth of capil-
laries from existing vessels, presumably facilitated by
hypoxia, and arteriogenesis, the in situ enlargement of
muscular collateral vessels from preexisting arteriolar
anastomoses.8-13 It has been suggested that arteriogen-
esis, or collateral vessel development, occurring proxi-
mal to distal ischemic beds is most important for efficient
revascularization and the rapid development of stable
nurturing vessels that provide extensive blood flow and
are not subject to regression in the setting of acute
ischemia.32 In contrast, the capillary networks that rap-
idly develop in the setting of ischemia (angiogenesis)
might undergo involution and are theoretically not ideal
permanent conduits for a robust revascularization that are
critical for providing nutrient and oxygen delivery to the
distal ischemic tissues.32 Given the present histologic
studies suggesting the primacy of arteriogenic processes
after AdEgr administration, improved ischemic lesion
scores in the present study suggest that an Egr-1–medi-
ated pathway might provide for collateral development
144 The Journal of Thoracic and Cardiovascular Surgery ● Janusufficient to enhance distal tissue bed perfusion. On the
other hand, it is also possible that other trophic effects of
Egr-1 or its downstream mediators, such as akt, are at
least possibly responsible for the preservation of tissue
integrity noted in the present studies, independent of the
effects of Egr-1 on revascularization mechanisms.
Prior animal studies have shown that arteriogenesis in-
volves rapid proliferation of preexisting arteriolar shunts, fol-
lowed by remodeling processes.8-13,33,34 This process has a
specific temporal dynamic, characterized by maximal prolifer-
ation in the first week after vascular occlusion, that has a
biphasic progression that occurs independently of angiogene-
sis. Such considerations are consistent with the results of the
current study.
Our finding that a primarily arteriogenic therapy can be
used to enhance perfusion might be especially meaningful
in that the near-normalization of distal perfusion mediated
by AdEgr-1 demonstrated in the current study exceeds
results that we have previously obtained with the analogous
delivery of angiogenic mediators, such as VEGF, in the
described hind-limb excision model (data not shown).
These findings suggest both the potency of arteriogenic
pathways as mediators of physiologic perfusion and the
potential efficacy of transcription factors, as opposed to the
administration of individual growth factors, in such thera-
peutic revascularization strategies.34
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Discussion
Dr Frank W. Sellke (Boston, Mass). This study very elegantly
and convincingly shows the importance of the early growth re-
sponse 1 (Egr-1) gene in the development of collateral vessels and
especially the role in the arteriogenesis process. However, there
The Journal of Thoraciare many transcription factors and growth factors that have been
examined that have demonstrated excellent results in providing
increased blood flow to ischemic tissues in animal models. How-
ever, human trials have essentially been negative to date.
Do you think Egr-1 bypasses some of those endothelial-specific
mediators or other mediators of angiogenesis and arteriogenesis
that might be missing in patients with atherosclerosis, diabetes,
hypertension, and other risk factors for coronary artery disease and
a poor angiogenic response, or would this also be subject to those
similar influences diminishing the angiogenic effect?
What is the role of shear forces in the regulation of Egr-1
expression? Is this one of the common pathways leading to the
arteriogenesis process?
Finally, you showed an approximately 20% increase in perfu-
sion at 21 days. Do you think this will be sufficient to provide
enough blood flow to treat the ischemia?
Dr Rosengart. Thank you, Frank. Those are all very important
questions.
In terms of the importance of Egr, it is certainly not completely
clear at this point, but what we were most struck by is the absolute
lack of reperfusion in our knockout animals, suggesting in fact that
Egr might be at the top of the molecular pyramid governing revas-
cularization, and that even though other mechanisms, such as isch-
emic upregulation of vascular endothelial growth factor, for example,
should in theory be intact, in fact they did not seem to play a
significant role in terms of revascularization. Therefore it is conceiv-
able, although certainly not proved, with all the overlap in different
molecular pathways, that Egr is certainly very important if not abso-
lutely mandatory for revascularization.
Shear forces do play a very important role in Egr upregulation, and
this is one of the things that attracted us to Egr as an interesting
messenger. Certainly increases in shear forces that upregulate Egr,
and is evidence as well that decreases in shear forces also play a role.
Which of these forces is causing upregulation of Egr in this model is
not clear, but we have certainly shown upregulated Egr in the vascu-
lature after occlusion.
Finally, changes that we see in animal models, as you know and
have so elegantly demonstrated, do not necessarily translate into
the clinical scenario, and certainly this is an area that will need to
be investigated.
Dr Michael Mann (San Francisco, Calif). I am sure you are familiar
with the work of Wolfgang Schaper in Germany, who originally empha-
sized the role of these mechanical forces but has more recently looked at
inflammation as a key mediator of the arteriogenesis response. Do you
have any data that suggest exactly where the expression of Egr and the
activity of Egr is essential? Is it actually in the endothelium or in the blood
vessel? Is it active actually in your gene transfer model in the muscles,
and what are the implications for potential hematherapies?
Dr Rosengart. Wolfgang Schaper is truly a pioneer in the area and
has been an inspiration specifically in this work. If you look at the
molecular pathways of Egr and monocyte chemotactic factor, for exam-
ple, which is an area of tremendous interest for Professor Schaper, Egr is,
in fact, upstream of monocyte chemotactic protein 1 and again, theoret-
ically, is controlling in that manner. It might take precedence over in-
flammation, although certainly that would need to be looked at. We have
demonstrated that Egr is upregulated within the vasculature wall—we
have not isolated which cell type—which certainly makes sense in terms
of Egr-1 being responsive to changes in shear stress.
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